ABT — Abbott Laboratories Balance Sheet
0.000.00%
- $223.72bn
- $230.14bn
- $41.95bn
- 96
- 41
- 81
- 85
Annual balance sheet for Abbott Laboratories, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 7,148 | 10,249 | 10,170 | 7,279 | 7,967 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 6,414 | 6,487 | 6,218 | 6,565 | 6,925 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 20,441 | 24,239 | 25,224 | 22,670 | 23,656 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 10,130 | 10,112 | 10,278 | 11,276 | 11,733 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 72,548 | 75,196 | 74,438 | 73,214 | 81,414 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11,907 | 13,105 | 15,489 | 13,841 | 14,157 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 39,764 | 39,394 | 37,752 | 34,611 | 33,750 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 32,784 | 35,802 | 36,686 | 38,603 | 47,664 |
| Total Liabilities & Shareholders' Equity | 72,548 | 75,196 | 74,438 | 73,214 | 81,414 |
| Total Common Shares Outstanding |